Graphite's hopes for sickle cell 'cure' blunted after first patient dosed...

[cafead]

via A year and a half after exceeding expectations with its $238 million IPO, Graphite Bio has hit a major roadblock as an adverse event caused the gene-therapy-focused biotech to pause its lead program.

article source